menu
    • menu
    [{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cadila Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Lipidor AB \/ Lipidor AB","highestDevelopmentStatusID":"8","companyTruncated":"Lipidor AB \/ Lipidor AB"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Menarini"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Calcitriol receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lipidor AB

    Menu

    Lipidor AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lipidor Updates on Phase III Study of AKP02 In Treatment of Psoriasis - Half of Patients Now Recruited

    Details : Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.

    Product Name : AKP02

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 20, 2022

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabidiol

    Therapeutic Area : Dermatology

    Study Phase : Preclinical

    Sponsor : Cannassure Therapeutics

    Deal Size : $0.4 million

    Deal Type : Expanded Collaboration

    DEALS_DEV arrow-down

    Lipidor Submits New Patent Application and Expands Collaboration with Cannassure Using Lipidor's AKVANO® Tech...

    Details : Based on new IP (intellectual property), the scope of the collaboration agreement has expanded to include a new patent family covering innovative new AKVANO® topical formulations.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    October 29, 2021

    Lead Product(s) : Cannabidiol

    Therapeutic Area : Dermatology

    Highest Development Status : Preclinical

    Sponsor : Cannassure Therapeutics

    Deal Size : $0.4 million

    Deal Type : Expanded Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Menarini

    Deal Size : $83.1 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Lipidor AB Licence Agreement Grants Menarini Group Exclusive Rights to Two New Psoriasis Drug Candidates for P...

    Details : Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.

    Product Name : AKP01

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 01, 2021

    Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Menarini

    Deal Size : $83.1 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lipidor- Update on the Company's Phase III Clinical Trial of Drug Candidate AKP02 for Treatment of Psoriasis

    Details : AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.

    Product Name : AKP02

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 22, 2021

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabidiol

    Therapeutic Area : Dermatology

    Study Phase : Undisclosed

    Sponsor : Cannassure Therapeutics

    Deal Size : $0.4 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Lipidor and Cannassure Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based o...

    Details : Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 18, 2021

    Lead Product(s) : Cannabidiol

    Therapeutic Area : Dermatology

    Highest Development Status : Undisclosed

    Sponsor : Cannassure Therapeutics

    Deal Size : $0.4 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Recipient : Cadila Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate

    Details : Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spr...

    Product Name : AKP-02

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 07, 2020

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Recipient : Cadila Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House

    Details : Company has successfully completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and is planning for a licensing project.

    Product Name : AKP02

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 07, 2020

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed

    Lipidor AB

    Sweden arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against ...

    Details : Both Lipidor's AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo.

    Product Name : AKP01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 24, 2020

    Lead Product(s) : Calcipotriol

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth